Use of gene therapy to study lung infection and immunity

Gene Therapy in Lung Disease

Volumn , Issue , 2002, Pages 193-218

  Prellop, Perri ^a   Kolls, Jay K ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 30644475104     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (154)

1. Reynolds HY. Host defense impairments that may lead to respiratory infections. Clin Chest Med 1987; 8(3):339-358.
2. Fels AOS, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986; 60:353-369.
3. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141:471-501.
4. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79:319-326.
5. Kindler V, Sappino A-P, Grau GE, Piguet P-F, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-740.
6. Lai WC, Bennett M, Pakes SP, Kumar V, Steutermann D, Owusu I, et al. Resistance to Mycoplasma pulmonis mediated by activated natural killer cells. J Infect Dis 1990; 161:1269-1275.
7. Nikaido Y, Yoshida S, Goto Y, Mizuguchi Y, Kuroiwa A. Macrophage-activating T-cell factor(s) produced in an early phase of Legionella pneumophila infection in guinea pigs. Infect Immun 1989; 57(11):3458-3465.
8. Ebrahimi B, Dutia BM, Brownstein DG, Nash AA. Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon- gamma receptor knockout mice. Am J Pathol 2001; 158(6):2117-2125.
9. Li C, Corraliza I, Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi infection in mice. Infect Immun 1999; 67(9): 4435-4442.
10. Zhang Y, Denkers EY. Protective role for interleukin-5 during chronic Toxoplasma gondii infection. Infect Immun 1999; 67(9):4383-4392.
11. Wei XQ, Leung BP, Niedbala W, Piedrafita D, Feng GJ, Sweet M, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163(5):2821-2828.
12. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474.
13. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316(15):889-897.
14. Cohen J. IL-12 deaths: explanation and a puzzle (news). Science 1995; 270(5238): 908.
15. Nathan CF, Prendergast TJ, Wiebe ME, Stanley ER, Platzer E, Remold HG, et al. Activation of human macrophages. Comparison of other cytokines with interferon- gamma. J Exp Med 1984; 160:600-605.
16. Black CM, Catterall JR, Remington JS. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma. J Immunol 1987; 138:491-495.
17. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158:670-689.
18. Collart MA, Belin D, Vassalli JD, de Kossodo S, Vassalli P. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986; 164:2113-2118.
19. Luedke C, Cerami A. Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. J Clin Invest 1990; 86:1234-1240.
20. Kolls JK, Xie J, Lei D, Greenberg S, Summer WR, Nelson S. Differential effects of in vivo ethanol on LPS-induced TNF and nitric oxide production in the lung. Am J Physiol Lung Cell Mol Physiol 1995; 268:L991-L998.
21. Beck JM, Liggit HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of interferon-gamma. Infect Immun 1991; 59:3859-3862.
22. Murray HW. Interferon-gamma, the activated macrophage, and host defense against antimicrobial challenge. Ann Intern Med 1988; 108:595-608.
23. Murray HW, Gellene RA, Libby DM, Rothermel CD, Rubin BY. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. J Immunol 1985; 135:2374-2377.
24. Vecchiarelli A, Todisco T, Puliti M, Dottorini M, Bistoni F. Modulation of anticandida activity of human alveolar macrophages by interferon-gamma or interleu- kin-1-alpha. Am J Respir Cell Mol Biol 1989; 1:49-55.
25. Wu-Hsieh B. Relative susceptibilities of inbred mouse strains C57BL/6 and A/J to infection with Histoplasma capsulatum Infect Immun 1989; 57:3788-3792.
26. Zhong G, Peterson EM, Czarniecki CW, Schrieber RD, De La Maza LM. Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. Infect Immun 1989; 57:152-157.
27. Chiang Y-W, Roth JA, Andrews JJ. Influence of recombinant interferon gamma and dexamethasone on pneumonia attributable to Heamophilus somnus in calves. Am J Vet Res 1990; 51:759-762.
28. Suzuki Y, Joh K, Kobayashi A. Tumor necrosis factor-independent protective effect of recombinant IFN-gamma against acute toxoplasmosis in T-cell deficient mice. J Immunol 1991; 147:2728-2733.
29. Skerrett SJ, Martin TR. Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994; 149:5058.
30. Steinmuller C, Franke-Ullmann G, Lohmann-Matthes ML, Emmendorffer A. Local activation of nonspecific defense against a respiratory model infection by application of interferon-gamma: comparison between rat alveolar and interstitial lung macrophages. Am J Respir Cell Mol Biol 2000; 22(4):481-490.
31. Brunda MJ. Interleukin-12 (Review). J Leukoc Biol 1994; 55(2):280-288.
32. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170(3):827-845.
33. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177(5): 1505-1509.
34. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/C mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155(5):2515-2524.
35. Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol 1995; 155(5):2545-2556.
36. Wagner RD, Steinberg H, Brown JF, Czuprynski CJ. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathogen 1994; 17(3):175-186.
37. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84(3):423-432.
38. Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, et al. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 1995; 155(2):785-795.
39. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia J Immunol 1996; 157(7):3006-3012.
40. Geng Y, Berencsi K, Gyulai Z, Valyi-Nagy T, Gonczol E, Trinchieri G. Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection. Infect Immun 2000; 68(4):2245-2253.
41. Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 1989; 89(2):612-616.
42. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGilli-cuddy DC, et al. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996; 173:159-165.
43. Tateda K, Moore TA, Newstead MW, Tsai WC, Zeng X, Deng JC, et al. Chemo- kine-dependent neutrophil recruitment in a murine model of Legionella pneumonia: potential role of neutrophils as immunoregulatory cells. Infect Immun 2001; 69(4): 2017-2024.
44. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82(24):8667-8671.
45. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316:379-385.
46. Beutler B, Milsark I, Cerami A. Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 1985; 229:869-871.
47. Bonavida B, Paubert-Braquet M, Hosford D, Braquet P. The involvement of platlet- actiating factor (PAF)-induced monocyte activation and tumor necrosis factor production in shock. Prog Clin Biol Res 1989; 308:485-489.
48. Jacob CO. Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch. Immunol Today 1992; 13:122-125.
49. Jacob CO, McDevitt HO. Tumor necrosis factor-alpha in autoimmune ‘lupus’ nephritis. Nature 1988; 331:356-358.
50. Piquet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute graft-versus-host disease. J Exp Med 1987; 166:1280-1289.
51. Bonavida B. Immunomodulatory effect of tumor necrosis factor. Biotherapy 1991; 3:127-133.
52. Cerami A, Beutler B. The role of cachectin/TNF in endotoxin shock and cachexia. Immunol Today 1988; 9:28-31.
53. Kolls JK, Nelson S, Summer WR. Recombinant cytokines and pulmonary host defense. Am J Med Sci 1993; 306(5):330-335.
54. Nelson S, Bagby GJ, Bainton B, Wilson LA, Thompson JJ, Summer WR. Compart- mentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989; 159: 189-194.
55. Blanchard DK, Djeu JY, Klein TW, Friedman M, Stewart WE. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol 1988; 4342:429-435.
56. Chen W, Havell EA, Harmsen A. Importance of endogenous tumor necrosis factor- alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60:1279-1284.
57. Adams LB, Mason CM, Kolls JK, Scollard D, Krahenbuhl JL, Nelson S. Exacerbation of acute and chronic murine tuberculosis by administration of a TNF receptor expressing adenovirus. J Infect Dis 1995; 171:400-405.
58. Moore KW, O’Garra A, de Waal MR, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-190.
59. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
60. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147(11):3815-3822.
61. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177(2):547-550.
62. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89(5):1890-1893.
63. Qin L, Ding Y, Pahud DR, Robson ND, Shaked A, Bromberg JS. Adenovirus- mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997; 8(11):1365-1374.
64. Drazan KE, Wu L, Olthoff KM, Jurim O, Busuttil RW, Shaked A. Transduction of hepatic allografts achieves local levels of viral IL-10 which suppress alloreactivity in vitro. J Surg Res 1995; 59(1):219-223.
65. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998; 160(11):5213-5220.
66. Boehler A, Chamberlain D, Xing Z, Slutsky AS, Jordana M, Gauldie J, et al. Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of Bronchiolitis obliterans Hum Gene Ther 1998; 9(4):541-551.
67. Xing Z, Ohkawara Y, Jordana M, Graham FL, Gauldie J. Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Ther 1997; 4(2):140-149.
68. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL- 10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997; 159(6):2858-2866.
69. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in amurine model of Klebsiella pneumonia J Immunol 1995; 155(2):722-729.
70. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174(5):994-1000.
71. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines (see comments). J Exp Med 1996; 183(6):2593-2603.
72. Schwarzenberger P, La R, V, Miller A, Ye P, Huang W, Zieske A, et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998; 161(11):6383-6389.
73. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160(7):3513-3521.
74. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162(4):2347-2352.
75. Hoshino H, Lotvall J, Skoogh BE, Linden A. Neutrophil recruitment by interleukin- 17 into rat airways in vivo. Role of tachykinins. Am J Respir Crit Care Med 1999; 159(5 Pt 1):1423-1428.
76. Hoshino H, Laan M, Sjostrand M, Lotvall J, Skoogh BE, Linden A. Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J Allergy Clin Immunol 2000; 105(1 Pt 1):143-149.
77. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. In press.
78. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-733.
79. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development (see comments). Sci 1998; 282(5392):1281-1284.
80. Nelson S, Bagby G, Summer WR. Alcohol suppresses lipopolysaccharide-induced tumor necrosis factor activity in serum and lung. Life Sci 1989; 44:673-676.
81. Zhang Z, Cork J, Ye P, Lei D, Schwarzenberger PO, Summer WR, et al. Inhibition of TNF-alpha processing and TACE-mediated ectodomain shedding by ethanol. J Leukoc Biol 2000; 67(6):856-862.
82. Wang CY, Fu SM, Kunkel HG. Isolation and immunological characterization of a major surface glycoprotein (gp54) preferentially expressed on certain human B cells. J Exp Med 1979; 149(6):1424-1437.
83. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180(4):1263-1272.
84. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357(6373):80-82.
85. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992; 176(6):1543-1550.
86. Subauste CS, Wessendarp M, Sorensen RU, Leiva LE. CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. J Immunol 1999; 162(11):6690-6700.
87. Hayashi T, Rao SP, Meylan PR, Kornbluth RS, Catanzaro A. Role of CD40 ligand in Mycobacterium avium infection. Infect Immun 1999; 67(7):3558-3565.
88. Chaussabel D, Jacobs F, de Jonge J, de Veerman M, Carlier Y, Thielemans K, et al. CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun 1999; 67(4):1929-1934.
89. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998; 161(9):4563-4571.
90. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135.
91. Oz HS, Hughes WT, Rehg JE, Thomas EK. Effect of CD40 ligand and other immu- nomodulators on Pneumocystis carinii infection in rat model. Microb Pathogen 2000; 29(3):187-190.
92. Wiley JA, Harmsen AG. CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995; 155(7):3525-3529.
93. Hwang Y, Nahm MH, Briles DE, Thomas D, Purkerson JM. Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L. Infect Immun 2000; 68(2):511-517.
94. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996; 14:101-130.
95. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997; 159:137-154.
96. Alcami A, Smith GL. Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Immunol Today 1995; 16(10):474-478.
97. Parry CM, Simas JP, Smith VP, Stewart CA, Minson AC, Efstathiou S, et al. A broad spectrum secreted chemokine binding protein encoded by a herpes virus. J Exp Med 2000; 191(3):573-578.
98. van B, V, Barrett J, Tiffany HL, Fremont DH, Murphy PM, McFadden G, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000; 74(15):6741-6747.
99. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 68(6):793-806.
100. Gilliand G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: detection and quantition by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1992; 87:2725-2729.
101. Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Mehrad B, Bucknell KA, et al. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. Hum Gene Ther 1999; 10(6): 899-909.
102. Foley R, Driscoll K, Wan Y, Braciak T, Howard B, Xing, et al. Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung. Am J Pathol 1996; 149(4):1395-1403.
103. Kolls JK, Lei D, Stoltz D, Zhang P, Schwarzenberger PO, Ye P, et al. Adenoviral- mediated interferon-gamma gene therapy augments pulmonary host defense of ethanol-treated rats. Alcohol Clin Exp Res 1998; 22(1):157-162.
104. Shellito JE, Zheng M, Ye P, Ruan S, Shean MK, Kolls J. Effect of alcohol consumption on host release interleukin-17 during pulmonary infection with Klebsiella pneumoniae. Alcohol Clin Exp Res 2001; 25(6):872-881.
105. Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa Rev Infect Dis 1983; 5(2):279-313.
106. Bowton DL. Nosocomial pneumonia in the ICU—year 2000 and beyond. Chest 1999; 115(3 Suppl):28S-33S.
107. Lei D, Lancaster JR, Jr, Joshi MS, Nelson S, Stoltz D, Bagby GJ, et al. Activation of alveolar macrophages and lung host defenses using transfer of the interferon- gamma gene. Am J Physiol Lung Cell Mol Physiol 1997; 272(5):L852-L859.
108. Chen GH, Reddy RC, Newstead MW, Tateda K, Kyasapura BL, Standiford TJ. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165(11):6496-6503.
109. Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen- specific humoral immunity independent of CD4+ T cells. Nat Med 2000; 6(10): 1154-1159.
110. Fauci AS, Macher AM, Longo DL, Lane HC, Rook AH, Masur H, et al. NIH Conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984; 100:92-106.
111. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saahet A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I. N Engl J Med 1990; 322:155-161.
112. Kolls JK, Habetz S, Shean MK, Vazquez C, Brown JA, Lei D, et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J Immunol 1999; 162(5):2890-2894.
113. Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332(16):1077-1082.
114. Ampel NM, Bejarano GC, Salas SD, Galgiani JN. In vitro assessment of cellularimmunity in human coccidioidomycosis: relationship between dermal hypersensitivity, lymphocyte transformation, and lymphokine production by peripheral blood mononuclear cells from healthy adults. J Infect Dis 1992; 165(4):710-715.
115. Beaman L, Pappagianis D, Benjamini E. Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect Immun 1977; 17(3):580-585.
116. Corry DB, Ampel NM, Christian L, Locksley RM, Galgiani JN. Cytokine production by peripheral blood mononuclear cells in human coccidiodomycosis. J Infect Dis 1996; 174(2):440-443.
117. Cox RA, Kennell W, Boncyk L, Murphy JW. Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis. Infect Immun 1988; 56(1):13-17.
118. Cox RA, Magee DM. Protective immunity in coccidioidomycosis. Res Immunol 1998; 149(4-5):417-428.
119. Magee DM, Cox RA. Interleukin-12 regulation of host defenses against Coccidioides immitis Infect Immun 1996; 64(9):3609-3613.
120. Jiang C, Magee DM, Cox RA. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis. Infect Immun 1999; 67(6):2996-3001.
121. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991; 266(2):225-230.
122. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2(8618):983-986.
123. Starnbach MN, Beven MJ, Lampe MF. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis J Immunol 1994; 153(11):5183-5189.
124. Lampe MF, Wilson CB, Bevan MJ, Starnbach MN. Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection. Infect Immun 1998; 66(11):5457-5461.
125. Svanholm C, Bandholtz L, Castanos-Velez E, Wigzell H, Rottenberg ME. Protective DNA immunization against Chlamydia pneumoniae Scand J Immunol 2000; 51(4):345-353.
126. Penttila T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, et al. Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine 2000; 19(9-10):1256-1265.
127. Murdin AD, Dunn P, Sodoyer R, Wang J, Caterini J, Brunham RC, et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis 2000; 181(Suppl 3):S544-S551.
128. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull WHO 1994; 72(2):213-220.
129. Sudre P, ten DG, Kochi A. Tuberculosis: a global overview of the situation today. Bull WHO 1992; 70(2):149-159.
130. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178(6): 2243-2247.
131. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178(6):2249-2254.
132. Tascon RE, Stavropoulos E, Lukacs KV, Colston MJ. Protection against Mycobacterium tuberculosis infection by CD8 + T cells requires the production of gamma interferon. Infect Immun 1998; 66(2):830-834.
133. Rodriguez FH, Nelson S, Kolls JK. Cytokine therapeutics for infectious diseases. Curr Pharm Des 2000; 6(6):665-680.
134. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62(6):2536-2544.
135. Hubbard RD, Flory CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 1992; 87(1):94-98.
136. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992; 60(11):4781-4792.
137. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT, et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis Immunology 1995; 85(3):502-508.
138. Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18(20):2155- 2163.
139. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis Infect Immun 1999; 67(4):1702-1707.
140. Baldwin SL, D’Souza C, Roberts AD, Kelly BP, Frank AA, Lui MA, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66(6):2951-2959.
141. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2(8):893-898.
142. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69(2):681-686.
143. Tanghe A, D’Souza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding AG85 by protein boosting. Infect Immun 2001; 69(5):3041-3047.
144. Delogu G, Howard A, Collins FM, Morris SL. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimyco- bacterial immunity. Infect Immun 2000; 68(6):3097-3102.
145. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, etal. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400(6741): 269-271.
146. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4):422-434.
147. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89(4):405-421.
148. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151(4):2032- 2040.
149. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/C mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994; 68(8):5321-5325.
150. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992; 10(7):475-484.
151. Crowe JE, Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11(14): 1395-1404.
152. Hussell T, Spender LC, Georgiou A, O’Garra A, Openshaw PJ. Th1 and TH2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J Gen Virol 1996; 77(pt 10):2447-2455.
153. Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci USA 1999; 96(5):2367-2372.
154. Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncitial virus in the BALB/C mouse. J Immunol 2000; 164(11):5913-5921.